Trial Condition(s):

Atrial Fibrillation

Registry study of adherence to treatment with rivaroxaban and warfarin in patients with atrial fibrillation, as requested by the Dental and Pharmaceutical Benefits Board (TLV)

Bayer Identifier:

18491

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

Not Available

Study Completed

Trial Purpose

This is a retrospective registry study to describe and compare the adherence among AF patients initiating treatment with rivaroxaban (without previous warfarin or NOAC use) with those initiating treatment with warfarin (with and without previous warfarin or NOAC use). It is a requirement by The Dental and Pharmaceutical Benefits Board (TLV) in Sweden to provide data on a comparison of adherence to NOAC treatment vs. warfarin for newly treated patients in atrial fibrillation. Several Swedish registries will be utilized.

Inclusion Criteria
No Inclusion Criteria Available
Exclusion Criteria
No Exclusion Criteria Available

Trial Summary

Enrollment Goal
57558
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Xarelto (Rivaroxaban, BAY59-7939)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many locations, Sweden

Status
Completed
 

For details, please refer to trial results

Additional Information